KalVista Appoints Brian Piekos as Chief Financial Officer
September 10 2024 - 6:30AM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
that Brian Piekos has joined the Company as Chief Financial Officer
(CFO). Mr. Piekos is an experienced public company CFO who brings a
demonstrated track record of successfully leading companies across
the biotechnology sector.
“Brian’s deep industry experience and expertise in managing
financial and capital strategies makes him a strong addition to
KalVista as we prepare for the commercialization of sebetralstat,”
said Ben Palleiko, Chief Executive Officer at KalVista. “I’m
excited to welcome Brian to KalVista, as he shares our commitment
to patients and a results-driven approach to business
excellence.”
“I am excited to join KalVista at such an important time for the
Company. The combination of a thoughtful, seasoned team, the
breadth of positive data generated for sebetralstat, and the
regulatory reviews underway, puts the Company in prime position to
become a successful commercial organization,” said Mr. Piekos. “I
look forward to embarking on this journey of bringing forward a
novel therapy that has the potential to transform the treatment of
hereditary angioedema.”
Brian Piekos has more than 25 years of financial and strategic
planning experience in the biopharmaceutical industry. He joins
KalVista from Elicio Therapeutics where he served as CFO and was
responsible for launching Elicio as a public company. Previously,
he served as CFO for Gemini Therapeutics and as Executive Vice
President, CFO and Treasurer at AMAG Pharmaceuticals. Mr. Piekos
held leadership roles in corporate finance, tax and treasury at
Cubist Pharmaceuticals and began his career as a healthcare
investment banker at Needham & Company and Leerink
Partners.
Mr. Piekos earned his B.A. in biochemistry from Ithaca College,
an M.S. in molecular biology from the University of Massachusetts
Medical School, and his MBA from the Simon Business School at the
University of Rochester.
On September 9, 2024 Mr. Piekos was granted inducement options
to purchase 100,000 shares of the Company’s Common Stock as
inducement to Mr. Piekos’ entering into employment with KalVista.
The options were granted in accordance with Nasdaq Listing Rule
5635(c)(4). The options have an exercise price of $11.87 per share,
which was equal to the closing price of the Company’s Common Stock
on the grant date. The options will vest over a four year period
with (i) 1/4th of the total shares subject to the options vesting
on the one year anniversary of Mr. Piekos’ start date and (ii)
thereafter, 1/48th of the total number of shares underlying the
options vesting on each monthly anniversary of the vesting
commencement date, which is subject to Mr. Piekos’ continued
service through each vesting date. Each stock option has a 10-year
term and is subject to the terms and conditions of the Company’s
2021 Amended and Restated Inducement Plan and a stock option
agreement covering the grant.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical
company focused on the development and delivery of oral medicines
for diseases with significant unmet need. KalVista announced
positive phase 3 data from the KONFIDENT trial for its oral,
on-demand therapy, sebetralstat for HAE in February 2024. The
Company’s NDA for sebetralstat has been accepted by the FDA with a
PDUFA goal date of June 17, 2025. In addition, KalVista received
validation of its MAA from the EMA in August 2024. KalVista expects
to file for approval in the UK, Japan, and other countries later in
2024.
For more information about KalVista, please visit
www.kalvista.com or follow on social media at
@KalVista and LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and its results, our ability to commence clinical
studies or complete ongoing clinical studies, including our
KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory
approvals for sebetralstat and other candidates in development, the
success of any efforts to commercialize sebetralstat, the ability
of sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2024, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240910275671/en/
Media: Jenn Snyder Vice President, Corporate Affairs
(857) 356-0479 jennifer.snyder@kalvista.com
Investors: Ryan Baker Head, Investor Relations (617)
771-5001 ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Aug 2024 to Sep 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Sep 2023 to Sep 2024